VIICTR Profiles
ORIT
Pediatrics CRA
Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma.
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. 2020 12; 26(12):1845-1851.
View in:
PubMed
subject areas
Adult
Aged
Antibodies, Monoclonal
Antibodies, Monoclonal, Humanized
Antineoplastic Agents, Immunological
Antineoplastic Combined Chemotherapy Protocols
Carcinoma
Cisplatin
CTLA-4 Antigen
Female
Humans
Male
Middle Aged
Neoplasm Staging
Programmed Cell Death 1 Receptor
Risk Factors
Urothelium
authors with profiles
JOHN N PAPADOPOULOS
COLIN P DINNEY
JAMES P ALLISON
ARLENE ODELIA SIEFKER-RADTKE
ASHISH KAMAT
SURENA MATIN
JOHN CHARLES ARAUJO
PADMANEE SHARMA
PAUL CORN
CHARLES CHUANHAI GUO
NEEMA NAVAI
JIANJUN GAO
ANDREW FUTREAL
AMISHI YOGESH SHAH
SANGEETA GOSWAMI